Literature DB >> 28463569

Early and Late Recurrent Epistaxis Admissions: Patterns of Incidence and Risk Factors.

Oded Cohen1,2, Hagit Shoffel-Havakuk1,2, Meir Warman1,2, Sharon Tzelnick1, Yaara Haimovich1, Gavriel D Kohlberg3, Doron Halperin1,2, Yonatan Lahav1,2.   

Abstract

Objective Epistaxis is a common complaint, yet few studies have focused on the incidence and risk factors of recurrent epistaxis. Our objective was to determine the patterns of incidence and risk factors for recurrent epistaxis admission (REA). Study Design Case series with chart review. Settings Single academic center. Subjects and Methods The medical records of patients admitted for epistaxis between 1999 and 2015 were reviewed. The follow-up period was defined as 3 years following initial admission. REAs were categorized as early (30 days) and late (31 days to 3 years) following initial admission. Logistic regression was used to identify potential predictors of REAs. Results A total of 653 patients were included. Eighty-six patients (14%) had REAs: 48 (7.5%) early and 38 (6.5%) late. Nonlinear incidence curve was demonstrated for both early and late REAs. Based on logistic regression, prior nasal surgery and anemia were independent risk factors for early REAs. According to multivariate analysis, thrombocytopenia was significantly associated with late REAs. Conclusion Early and late REAs demonstrate different risk predictors. Knowledge of such risk factors may help in risk stratification for this selected group of patients. All patients at risk should be advised on possible preventive measures. Patients at risk for early REA may benefit from a more proactive approach.

Entities:  

Keywords:  admissions; epistaxis; incidence; outcomes research; recurrent epistaxis

Mesh:

Year:  2017        PMID: 28463569     DOI: 10.1177/0194599817705619

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.

Authors:  Petar Stankovic; Robert Georgiew; Cornelius Frommelt; Sabine Hammel; Jan Wittlinger; Stephan Hoch; Danilo Obradovic; Nikolaos Dagres; Thomas Wilhelm
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 2.  Clinical Implications of Thrombocytopenia for the Cirrhotic Patient.

Authors:  Samuel H Sigal; Zachary Sherman; Arun Jesudian
Journal:  Hepat Med       Date:  2020-04-14

3.  Hospitalization for epistaxis: a population-based healthcare research study in Thuringia, Germany.

Authors:  Max Kallenbach; Andreas Dittberner; Daniel Boeger; Jens Buentzel; Holger Kaftan; Kerstin Hoffmann; Peter Jecker; Andreas Mueller; Gerald Radtke; Orlando Guntinas-Lichius
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-02       Impact factor: 2.503

4.  Risk Factors and Management for Epistaxis in a Hospitalized Adult Sample.

Authors:  Andrew Ross; Steven Engebretsen; Rebecca Mahoney; Samba Bathula
Journal:  Spartan Med Res J       Date:  2022-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.